Literature DB >> 28050712

Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention.

Mandeep S Virdee1, Derek Stewart2.   

Abstract

Background Updated evidence-based guidelines for the management of atrial fibrillation (AF) necessitate patient review, particularly with respect to oral anticoagulants, to ensure maximum health gain around stroke prophylaxis. Objective To quantify the level of anticoagulation utilisation in patients with a CHA2DS2-VASc ≥1/≥2 (male/female) according to evidence-based guidelines and to assess the impact of a pharmacist-led intervention to optimise therapy. Setting Fifteen general medical practices in Liverpool, North-West England with a practice population of 99,129. Method GRASP-AF software was employed to interrogate patient electronic medical records to identify and risk stratify AF patients (using CHA2DS2-VASc). A pharmacist then reviewed the medical records of those of patients not anticoagulated and with a CHA2DS2-VASc ≥1/≥2 (male/female). Recommendations were discussed with a general practitioner (GP) and those patients in whom the need for anticoagulation was agreed were invited for a consultation with either the pharmacist or GP and therapy optimised where appropriate. The GPs were responsible for managing those patients referred for diagnosis confirmation or further specialist opinion. Main outcome measure Proportion of patients eligible/not eligible for anticoagulation; proportions in whom anticoagulants initiated, refused, antiplatelets discontinued. Results Five hundred and twenty-three patients (31% of patients identified with AF and a CHA2DS2-VASc ≥1/≥2 (male/female)) were not receiving an anticoagulant (26 subsequently died or left the practice leaving 497). Three hundred and eighty-two (77%) pharmacist recommendations to a GP were agreed without modification. Following outcomes of diagnostic investigations and specialist referrals, 202 (41%) patients were candidates for anticoagulation, 251 (51%) were not eligible for anticoagulation, 103 (21%) were anticoagulated (56 warfarin, 47 DOAC). Conclusion A pharmacist-led intervention re-aligned oral anticoagulant therapy to the latest evidence based guidelines for stroke prophylaxis, whilst simultaneously correcting the over-utilisation of antiplatelet therapy.

Entities:  

Keywords:  Anticoagulant; Atrial fibrillation; Pharmacist; Stroke; United Kingdom

Mesh:

Substances:

Year:  2017        PMID: 28050712     DOI: 10.1007/s11096-016-0419-x

Source DB:  PubMed          Journal:  Int J Clin Pharm


  43 in total

Review 1.  Shared decision making in atrial fibrillation: where we are and where we should be going.

Authors:  Luke Seaburg; Erik P Hess; Megan Coylewright; Henry H Ting; Christopher J McLeod; Victor M Montori
Journal:  Circulation       Date:  2014-02-11       Impact factor: 29.690

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

Review 4.  Global burden of atrial fibrillation in developed and developing nations.

Authors:  Sumeet S Chugh; Gregory A Roth; Richard F Gillum; George A Mensah
Journal:  Glob Heart       Date:  2014-03

5.  Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation.

Authors:  A Howitt; D Armstrong
Journal:  BMJ       Date:  1999-05-15

6.  A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; J Biggs; E Drake; E Yetisir; R G Hart
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

7.  Pharmacist influence on prescribing in peripheral arterial disease (PIPER).

Authors:  Laura Brook-Barclay; Christopher L Delaney; Madeleine Scicchitano; Stephen Quinn; James I Spark
Journal:  Vasc Med       Date:  2014-02-20       Impact factor: 3.239

8.  A rising tide: the global epidemic of atrial fibrillation.

Authors:  Alvaro Alonso; Lindsay G S Bengtson
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

10.  Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK.

Authors:  Moloy Das; Lee Panter; Gareth J Wynn; Rob M Taylor; Neil Connor; Joseph D Mills; Paulus Kirchhof; Dhiraj Gupta
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

View more
  2 in total

1.  Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic.

Authors:  Xiaoye Li; Chengchun Zuo; Wenjing Lu; Ye Zou; Qing Xu; Xiaoyu Li; Qianzhou Lv
Journal:  Front Pharmacol       Date:  2020-08-21       Impact factor: 5.810

2.  Evaluation of a pharmacist-led shared decision-making in atrial fibrillation and patients' satisfaction-a before and after pilot study.

Authors:  Viviane Khalil; Samantha Blackley; Ashwin Subramaniam
Journal:  Ir J Med Sci       Date:  2020-08-17       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.